Dimerix Presents at Bioshares Summit 2026
Filed with ASX · · 23 pages · English
Earlier from Dimerix
- US Patent Granted for Dimerix New Asset DMX-652
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
- Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
- Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
- DMX-200 Available To Patients Via Post-Trial Access Pathways
Later from Dimerix
- Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
- Dimerix Receives US$10M Upfront Payment from Everest
- Appendix 4E and 2026 Annual Report
- Dimerix Secures A$34 Million Non-Dilutive Funding Facility
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix